Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 4
2002 2
2003 8
2004 4
2005 2
2006 1
2007 4
2008 3
2009 2
2010 5
2011 1
2012 3
2013 5
2014 8
2016 3
2017 4
2018 10
2019 5
2020 9
2021 4
2022 8
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

92 results
Results by year
Filters applied: . Clear all
Page 1
Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ. Lenz HJ. Oncologist. 2007 May;12(5):601-9. doi: 10.1634/theoncologist.12-5-601. Oncologist. 2007. PMID: 17522249 Free article. Review.
Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and symptom management. Rechallenge should be considered after complete resolution of all symptoms. Severe reactions may require treatment dis …
Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and sympt …
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH. Chung CH. Oncologist. 2008 Jun;13(6):725-32. doi: 10.1634/theoncologist.2008-0012. Oncologist. 2008. PMID: 18586928 Free article. Review.
Although generally better tolerated with less toxicity than conventional anticancer agents, monoclonal antibodies may cause infusion-related reactions like other infusional agents. The incidence of infusion reactions varies by agent, but severe events …
Although generally better tolerated with less toxicity than conventional anticancer agents, monoclonal antibodies may cause infusion- …
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Banerji U, et al. Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27. Lancet Oncol. 2019. PMID: 31257177 Clinical Trial.
BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. ...In the dose-expansion phase, treatment-related serious adverse events were reported in 16 (11 …
BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bou …
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Meric-Bernstam F, et al. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. Lancet Oncol. 2019. PMID: 30857956 Free PMC article. Clinical Trial.
Patients received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously). ...Serious treatment-emergent adverse events were reported in ten (18%) patients and two (4%) of …
Patients received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, t …
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. JAMA Oncol. 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. JAMA Oncol. 2021. PMID: 33480963 Free PMC article. Clinical Trial.
RESULTS: A total of 536 patients were randomized to receive margetuximab (n = 266) or trastuzumab (n = 270). The median age was 56 (27-86) years; 266 (100%) women were in the margetuximab group, while 267 (98.9%) women were in the trastuzumab group. ...Incidence of …
RESULTS: A total of 536 patients were randomized to receive margetuximab (n = 266) or trastuzumab (n = 270). The median age was 56 (2 …
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Li BT, et al. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989854 Free PMC article. Clinical Trial.
Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. ...The median progression-free survival was 5 months (95% CI, 3 to 9 months). Toxicities included grade 1 or 2 infusion reactions, thr …
Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. ...The m …
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Rugo HS, et al. ESMO Open. 2022 Aug;7(4):100553. doi: 10.1016/j.esmoop.2022.100553. Epub 2022 Aug 11. ESMO Open. 2022. PMID: 35964548 Free PMC article. Review.
This review discusses the management of common AEs and AEs of special interest in patients with HER2-positive unresectable/metastatic breast cancer, including nausea and vomiting, neutropenia, infusion-related reactions, alopecia, fatigue, ILD/pneumonitis, and left …
This review discusses the management of common AEs and AEs of special interest in patients with HER2-positive unresectable/metastatic breast …
Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients.
Sun D, Sarda G, Skube SJ, Blaes AH, Khairat S, Melton GB, Zhang R. Sun D, et al. Stud Health Technol Inform. 2017;245:599-603. Stud Health Technol Inform. 2017. PMID: 29295166 Free PMC article.
Infusion-related reactions (IRRs) are typical adverse events for breast cancer patients. ...Using the algorithm, an incidence of 6.4% of patients and 1.8% of doses for docetaxel, 8.7% and 3.2% for doxorubicin, 10.4% and 1.2% for paclitaxel, 16.1% and 1.1% for tra
Infusion-related reactions (IRRs) are typical adverse events for breast cancer patients. ...Using the algorithm, an incidence
Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?
Price L, Brunt AM. Price L, et al. Eur J Hosp Pharm. 2018 Nov;25(6):331-333. doi: 10.1136/ejhpharm-2016-001155. Epub 2017 Mar 16. Eur J Hosp Pharm. 2018. PMID: 31157052 Free PMC article.
Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. ...Fourteen patients received palliative, 73 adjuvant and 7 neoadjuvant trastuzumab.r. Two (2%) had a reaction to trastuzumab occur
Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. ...Fourteen
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Emens LA, et al. Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. Lancet Oncol. 2020. PMID: 33002436 Clinical Trial.
BACKGROUND: HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity of trastuzumab emtansine. ...Eligib …
BACKGROUND: HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab
92 results